A B S T R A C T Erythrocytes coated with varying amounts of human complement were used to detect lymphocytes with complement receptors from normal subjects and patients with chronic lymphocytic leukemia. The relationship between the percentage of lymphocytes rosetting and the quantity of C3 present on complement-coated erythrocytes were studied. Small quantities of C3 (<5 fg/erythrocyte) caused maximal rosetting of normal lymphocytes. Maximal rosetting with chronic lymphocytic leukemia lymphocytes was not reached until much greater amounts of C3 were used to coat the erythrocytes. This difference in sensitivity to erythrocyte-bound complement was not due to an increased fraction of complement receptor-bearing cells in the leukemic patients. This loss of sensitivity of the chronic lymphocytic leukemia lymphocyte for complement may play a role in the immune deficiency present in this disease.
INTRODUCTION
Several types of human cells have receptors for the third component of complement (C3 (1, 2) . Complement receptors on granulocytes, monocytes, and macrophages function in processes leading to phagocytosis (3) (4) (5) . The role of complement receptors on a subpopulation of human lymphocytes is less clear, but evidence is accumulating that these receptors are involved in some aspects of immune recognition (6, 7) . Lymphocytes with complement receptors (CRL)l have been considered bone marrow derived-(B) lymphocytes and serve a recognition function for the antibody-producing arm of the immune system (8) (9) (10) .
'Abbreviations used in this paper: CLL, chronic lymphocytic leukemia; CRL, complement-reactive lymphocytes; EC, complement-coated erythrocytes; VBS, veronal-buffered saline.
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CRL have receptors for several complement constituents, including C3b (the hemolytically active fragment of C3) and C3d (a degradation product of C3b produced by the action of the plasma enzyme, C3b inactivator) (11, 12) . There are also receptors for the fourth component of complement (12) . In such studies, complement sources from several species prepared in varying ways have been used to coat indicator erythrocytes for the rosetting procedures. However, the quantitative requirements for C3 of human lymphocyte receptors have not been extensively detailed.
To study lymphocyte receptors for human complement, we coated human erythrocytes with complement by reacting them with anti-I antibody and whole human serum (13) . We then used a quantitative anti-C3 consumption assay to measure the amount of the third component of complement added to these cells (14) . By varying the concentration of serum present during the erythrocyte preparation procedure, it was possible to obtain erythrocytes coated with C3, predominantly in the form of C3b. In this paper we describe the quantitative C3 requirements for the rosetting of complement-coated erythrocytes with CRL from normal subjects and patients with chronic lymphocytic leukemia (CLL).
METHODS
Preparation of complement-coated human erythrocytes. Methods of complement-coating of human erythrocytes by anti-I antibody and normal human serum, and the means of detecting C3 bound to these cells have previously been described and will be briefly reviewed here (13) (14) (15) . To determine the quantitative requirements for human C3 in rosetting with complement-reactive lymphocytes, we chose to investigate the consequences of complement activation in whole serum rather than that produced by fractions of purified human complement components. We did so to mimic more closely the natural situation, inasmuch as it appears that the reactions occurring in normal serum under such circumstances may differ from those occurring when purified components are used (16) .
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Whole blood from normal, type 0 subjects was obtained by venipuncture and placed in Alsever's solution (17) until used. Erythrocytes were then washed in isotonic veronal-buffered saline with 1% gelatin (VBS) (17, 18) and resuspended at a concentration of 4.4 x 108 cells/milliliter in VBS before use. Type-compatible serum obtained from normal donors was either used immediately or stored at -90 C until used. Anti-I antiserum was obtained as previously described (13) (kindly provided by Dr. W. F. Rosse). A reaction mixture containing 1 part erythrocytes, 1 part anti-I diluted 1:40 with VBS, and 1 part serum at dilutions of from 1:16 to 1:256 in VBS were incubated at 4°C for 30 min. The reaction mixture was then warmed slowly over 5 min at 37°C. 10 vol of 370 VBS were added immediately, and the cells were centrifuged. The cells were then washed four additional times with 370C VBS. A portion of the erythrocytes was resuspended in VBS to a concentration of 2.2 x 108/ml for determination of cell-bound C3, and the remainder diluted to a concentration of 1 x 107/ml for reaction with lymphocytes. This complement-coating procedure in dilute serum with a brief incubation at 37°C leads to the coating of erythrocytes with C3, predominantly in the form of C3b. This occurs because the cleavage of C3b to C3d by C3b inactivator requires higher serum concentrations or prolonged incubations at 37°C (14, 19) . The cold-reactive antibody is entirely removed by the 37°C washing procedure such that complement-coated erythrocytes (EC) are coated with complement components only (13, 14) .
Quantitation of membrane-bound C3. Membrane-bound C3 was measured by a previously described modification of the method of Borsos and Leonard (14, 20 (21) . An euglobulin precipitate of fresh human serum was applied to a DEAE column equilibrated with 0.03 M phosphate buffer, pH 8.1, and eluted with a gradient from 0.03 M phosphate buffer, pH 8.1, to 0.2 M NaH2PO4. The C3-containing fractions detected by immunoprecipitation were applied in a batch technique to hydroxyapatite which had been equilibrated with 8 mmho phosphate buffer, pH 7.9; the hydroxyapatite was then washed with 12 and 13 mmho phosphate buffer, pH 7.9, and the C3-containing material was eluted with 14.5 mmho phosphate buffer. The C3-containing supernatant fluid was then concentrated by the method of Alper and Rosen (22) . The purified human C3 produced a single band on microimmunoelectrophoresis against anti-whole human serum. (Meloy Laboratories, Inc., Springfield, V.) A single protein band was produced on polyacrylamide-gel disc electrophoresis. Anti-C3 antiserum was obtained by injecting rabbits with 0.75-2.0 mg of purified C3 emulsified in Freund's complete adjuvant. The rabbits were immunized three times over a 6-wk period, and the antisera used for this study were harvested 2 wk after the third immunization. The antisera were absorbed with bis-diazotized benzidine-aggregated IgG and human erythrocytes. When fresh human serum was examined by microimmunoelectrophoresis against these antisera, only a i,3C immunoprecipitin was obtained. When human serum, incubated at 40C for 2 wk was similarly examined, I31a and a2d immunoprecipitins were produced.
When partially aged serum was examined by this antiserum, B1ic P3a, and a2d arcs were present. C3-coated sheep cells were also prepared as previously described (13) (14) (15) .
Duplicate 0.1-ml serial three-fold dilutions of comple-ment-coated or control human erythrocytes were mixed with 0.1 ml of anti-C3 for 30 min. at an optimal complement concentration x 100. Optimal concentration of complement was the concentration resulting in the greatest number of lymphocytes forming rosettes for a sample from a given patient. The results of C3 rosette determinations using lymphocytes from six normal individuals and five CLL patients are shown in Fig. 2 . As was suggested by the comparison in Fig. 1 , cumulative results in Fig. 2 verify that considerably less C3 is necessary to induce rosetting with normal CRL than with CLL complement-reactive lymphocytes. When assayed with C3-coated erythrocytes, maximal rosetting of normal CRL occurred at levels of C3 of <5 fg per cell, whereas six to eight times as much surface-bound C3 was necessary to induce maximal rosetting of CLL CRL. Though the total lymphocyte number in each assay was kept constant, CLL lymphocytes generally contained a greater fraction of complement reactive cells. Thus, it could be argued that this effect is due to alterations in the ratio of CRL to erythrocytes. To test this possibility the rosette assay was performed at concentrations of erythrocytes varying from 1 x 107/ ml to 2.5 x 107/ml, all containing 5 fg of C3/cell. No significant change in the percentage of CLL CRL detectable at this C3 concentration was found. Moreover, two of the CLL patients included in this study had percentages of CRL approximating normal (21 and 23%). Lymphocytes from these two patients (one such study is shown in Fig. 1 ), likewise exhibited this decreased sensitivity.
To verify that the above binding was mediated by C3b, the effect of the conversion of erythrocyte-bound C3b to C3d upon rosetting was studied. EC with 5 fg of C3, predominantly in the form of C3b, were reincubated in undiluted autologous human serum in the absence of antibody at 37°C for 2 h. This procedure has been shown to convert erythrocyte-bound C3 to C3d (14) . Inasmuch as antibody is no longer present, no additional complement activation occurs. The ability of these erythrocytes to form rosettes with CLL and normal lymphocytes was restudied. As shown by a typical experiment in Table II (9) . Thus, Pepys postulated that complement activation is necessary for humoral recognition of some antigens (9) . It has been further suggested that lymphocyte activation proceeds by two sequential steps, antigen receptor binding serving as the first signal, and C3 receptor activation being the second (27) . Recent studies from this laboratory have shown that the interaction of complement-coated red cells, in the absence of foreign antigens, causes stimulation of RNA and protein synthesis in normal CR+ lymphocytes (28 Dameshek described CLL as a disease of the accumulation of immuno-incompetent lymphocytes (35) . As such, it represents an acquired immunodeficiency disease. As this disease progresses, the patients develop increased susceptibility to infection, decreased serum immunoglobulins, and increased autoantibodies (36) . These characteristics are similar to those of other immunodeficiency diseases. A number of abnormalities of the surface characteristics of leukemia lymphocytes have been described, including abnormal lectin binding (37) and altered intramembraneous Ig redistribution ("capping") (24) . Here 
